DUBLIN – Spybiotech Ltd. raised $32.5 million to move into clinical trials its first in-house vaccine program based on its Spycatcher/Spytag protein conjugation technology. The company is gearing up to start a phase I trial of a vaccine directed against cytomegalovirus (CMV) early next year.

Theator Ltd., the artificial intelligence (AI)-powered surgical intelligence platform, has raised $15.5 million in a series A financing led by Insight Partners. The funds will be used to scale commercial operations and partnerships with U.S. providers, grow the company’s R&D team and secure its footprint in the field of AI-driven surgical planning, intraoperative support, and review. New investor Blumberg Capital also participated in the round, along with all existing investors including Nfx, Stageone Ventures, Kdt Ventures and Iangels.

Ascendum Capital, a health care-focused investment platform founded in 2020, acquired the majority of the shares of a developer of a disposable robotic system designed to navigate tricky vascular passages for an undisclosed amount. Yehuda, Israel-based Endoways Ltd. developed the technology in the Medx Xelerator and will move to Dinova Medtech’s Israeli incubator until its catheter laboratory-focused robot launches for commercial use.

Chinese cancer and autoimmune specialist Innocare Pharma Ltd. raised HK$3.04 billion ($392 million) in private placements with two Hillhouse Capital subsidiaries and Vivo Opportunity Fund to advance its pipeline, especially its core asset, the BTK inhibitor orelabrutinib.

CAJICA, Colombia – China’s Anticancer Bioscience, a company focused on developing precision oncology medicines, has raised ¥66 million (US$10.2 million) to expand its small-molecule and natural product screening libraries and move two programs into IND-enabling studies.

DUBLIN – After a COVID-19-induced delay that set it back most of last year, Interna Technologies BV has moved its first microRNA-based drug development program into the clinic and has also unveiled €18.5 million (US$22.4 million) in a series B funding round, which it completed in two stages.